Clinitech Laboratory Ltd
₹ 42.7
0.00%
19 May
- close price
About
Founded in 1990, Clinitech Laboratory Limited provides diagnostic and health testing and services.[1]
Key Points
- Market Cap ₹ 9.75 Cr.
- Current Price ₹ 42.7
- High / Low ₹ 121 / 38.2
- Stock P/E 27.1
- Book Value ₹ 41.8
- Dividend Yield 0.00 %
- ROCE 14.8 %
- ROE 12.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 1.02 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Upcoming result date: tomorrow
Profit & Loss
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
4.55 | 6.38 | 6.35 | 6.40 | |
3.72 | 5.31 | 4.99 | 5.41 | |
Operating Profit | 0.83 | 1.07 | 1.36 | 0.99 |
OPM % | 18.24% | 16.77% | 21.42% | 15.47% |
0.04 | 0.07 | 0.02 | 0.04 | |
Interest | 0.08 | 0.06 | 0.07 | 0.09 |
Depreciation | 0.25 | 0.38 | 0.45 | 0.44 |
Profit before tax | 0.54 | 0.70 | 0.86 | 0.50 |
Tax % | 25.93% | 27.14% | 29.07% | 26.00% |
0.40 | 0.51 | 0.61 | 0.37 | |
EPS in Rs | 6.00 | 3.40 | 4.07 | 2.20 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 12% |
TTM: | 1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -1% |
TTM: | -41% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 22% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|
Equity Capital | 0.67 | 1.50 | 1.50 | 1.68 | 2.28 |
Reserves | 0.72 | 0.35 | 0.88 | 1.87 | 7.27 |
0.54 | 0.89 | 1.03 | 0.87 | 0.01 | |
0.80 | 0.94 | 2.62 | 1.19 | 1.48 | |
Total Liabilities | 2.73 | 3.68 | 6.03 | 5.61 | 11.04 |
0.84 | 1.65 | 1.33 | 1.71 | 1.77 | |
CWIP | 0.08 | 0.41 | 0.56 | 0.94 | 1.00 |
Investments | 0.09 | 0.14 | 2.02 | 0.07 | 0.07 |
1.72 | 1.48 | 2.12 | 2.89 | 8.20 | |
Total Assets | 2.73 | 3.68 | 6.03 | 5.61 | 11.04 |
Cash Flows
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
0.38 | 0.96 | 1.25 | 0.11 | |
0.54 | -1.47 | -0.65 | -0.64 | |
-0.88 | 0.29 | 0.09 | 0.45 | |
Net Cash Flow | 0.04 | -0.22 | 0.68 | -0.08 |
Ratios
Figures in Rs. Crores
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 44.92 | 20.60 | 28.17 | 34.22 |
Inventory Days | 32.21 | 40.28 | 43.68 | 92.91 |
Days Payable | 164.61 | 130.90 | 124.79 | 116.14 |
Cash Conversion Cycle | -87.48 | -70.03 | -52.95 | 10.99 |
Working Capital Days | 48.13 | 25.74 | 9.77 | 57.60 |
ROCE % | 32.55% | 30.24% | 14.81% |
Documents
Announcements
-
Board Meeting Intimation for We Wish To Inform You That The Meeting Of The Board Of The Company Will Be Held On Friday, May 23, 2025 Through Video Conferencing At 11.30 AM (IST)
19 May - Board meeting on May 23 to approve FY25 audited results; trading window closed from April 1.
-
Non Applicability Disclosure W.R.T Large Corporate
16 Apr - Company not classified as Large Corporate under SEBI circular.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Apr - Disclosure under SEBI regulations for quarter ended March 31, 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On March 25, 2025 At The Registered Office Of The Company At 03.00 PM (IST).
25 Mar - Appointment of internal and secretarial auditors for 5 years.
- Closure of Trading Window 24 Mar
Annual reports
No data available.
Business Profile[1] The company performs over 150 tests in its centers, categorized into Biochemical Tests, Immunology Tests, Hematology Tests, Molecular Biology Tests, Serology Tests, Microbiology Tests, and Histopathology Tests.